Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

Shashi Gujar; Jonathan G. Pol; Youra Kim; Guido Kroemer

doi:10.1080/2162402X.2020.1794424

Repurposing CD8⁺ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?

Shashi Gujar, Jonathan G. Pol, Youra Kim, Guido Kroemer

Medicine

Résultat de recherche: Review article › examen par les pairs

12 Citations (Scopus)

Résumé

The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8⁺ T cells for cancer immunotherapy strategies.

Langue d'origine	English
Numéro d'article	1794424
Journal	OncoImmunology
Volume	9
Numéro de publication	1
DOI	https://doi.org/10.1080/2162402X.2020.1794424
Statut de publication	Published - janv. 1 2020

Note bibliographique

Funding Information:
This work was supported by grants from the Canadian Institutes of Health Research (CIHR), Beatrice Hunter Cancer Research Institute (BHCRI), and Dalhousie Medical Research Foundation (DMRF) to S.G. JGP is supported by the Association Française d’Hépatologie (AFEF); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Seerave Foundation. Y.K. is supported by CIHR Doctoral Fellowship and DMRF CIBC Graduate Studentship in Cancer Immunotherapies. GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)–Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China]GDW20171100085 and GDW20181100051], Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM).

Publisher Copyright:
© 2020, © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Oncology

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't
Review

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.1080/2162402X.2020.1794424

Autres fichiers et liens

Citer

@article{36c853cbaa084548908d66fe4a7e25e1,

title = "Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy: a positive aspect of the COVID-19 pandemic?",

abstract = "The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.",

author = "Shashi Gujar and Pol, {Jonathan G.} and Youra Kim and Guido Kroemer",

note = "Funding Information: This work was supported by grants from the Canadian Institutes of Health Research (CIHR), Beatrice Hunter Cancer Research Institute (BHCRI), and Dalhousie Medical Research Foundation (DMRF) to S.G. JGP is supported by the Association Fran{\c c}aise d{\textquoteright}H{\'e}patologie (AFEF); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Seerave Foundation. Y.K. is supported by CIHR Doctoral Fellowship and DMRF CIBC Graduate Studentship in Cancer Immunotherapies. GK is supported by the Ligue contre le Cancer ({\'e}quipe labellis{\'e}e); Agence National de la Recherche (ANR)–Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc{\'e}rop{\^o}le Ile-de-France; Chancellerie des universit{\'e}s de Paris (Legs Poix), Fondation pour la Recherche M{\'e}dicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China]GDW20171100085 and GDW20181100051], Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi{\`e}re; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). Publisher Copyright: {\textcopyright} 2020, {\textcopyright} 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2020",

month = jan,

day = "1",

doi = "10.1080/2162402X.2020.1794424",

language = "English",

volume = "9",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Repurposing CD8+ T cell immunity against SARS-CoV-2 for cancer immunotherapy

T2 - a positive aspect of the COVID-19 pandemic?

AU - Gujar, Shashi

AU - Pol, Jonathan G.

AU - Kim, Youra

AU - Kroemer, Guido

N1 - Funding Information: This work was supported by grants from the Canadian Institutes of Health Research (CIHR), Beatrice Hunter Cancer Research Institute (BHCRI), and Dalhousie Medical Research Foundation (DMRF) to S.G. JGP is supported by the Association Française d’Hépatologie (AFEF); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Seerave Foundation. Y.K. is supported by CIHR Doctoral Fellowship and DMRF CIBC Graduate Studentship in Cancer Immunotherapies. GK is supported by the Ligue contre le Cancer (équipe labellisée); Agence National de la Recherche (ANR)–Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Chancellerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); a donation by Elior; European Research Area Network on Cardiovascular Diseases (ERA-CVD, MINOTAUR); Gustave Roussy Odyssea, the European Union Horizon 2020 Project Oncobiome; Fondation Carrefour; High-end Foreign Expert Program in China]GDW20171100085 and GDW20181100051], Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière; the Seerave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); and the SIRIC Cancer Research and Personalized Medicine (CARPEM). Publisher Copyright: © 2020, © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.

AB - The COVID-19 pandemic has afflicted most countries on the planet. As a result, immunity against SARS-CoV-2, induced via natural infections or imminent vaccinations, is expected to develop in a large fraction of the global population. Here, we propose to exploit SARS-CoV-2-specific CD8+ T cells for cancer immunotherapy strategies.

UR - http://www.scopus.com/inward/record.url?scp=85088043873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088043873&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2020.1794424

DO - 10.1080/2162402X.2020.1794424

M3 - Review article

C2 - 32923158

AN - SCOPUS:85088043873

SN - 2162-4011

VL - 9

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 1794424

ER -